The submission is backed by clinical data from over 2,100 patients, including two pivotal Phase III trials in patients treated with trenibotulinumtoxinE for moderate to severe glabellar lines.

Pooja Lal, VP of strategy and commercial content at Veeva Systems, spoke with Pharmaceutical Executive about some of the ways ...

The level on tariffs on Chinese origin products is astronomical. We also have a 10% tariff on products from Europe, with a carve out for very specific pharmaceutical products. How long that will last ...

Chris Springate, CEO, ARC Medical, discusses how postoperative adhesions continue to cause chronic pain, infertility, and life-threatening complications—despite advances in surgical techniques and ...